-
2024-514394-22-00
6
2022-10-24
Actinic Keratosis
-
2023-508265-33-00
5
2022-10-13
Vasomotor symptoms caused by adjuvant endocrine therapy in women with,
-
2024-516438-36-00
4
2022-09-13
Patients with very low, low or intermediate risk myelodysplastic syndr
-
2023-506927-27-00
5
2022-08-29
Children with short stature either born small for gestational age or w
-
2023-509260-25-00
5
2022-07-12
Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
-
2023-505974-14-00
5
2022-06-23
Multiple Sclerosis (MS)
-
2023-506854-19-00
1
2022-05-19
Solid Tumors
-
2023-507131-38-00
5
2022-05-16
Neovascular Age-Related Macular Degeneration (nAMD)
-
2023-507469-24-00
4
2022-04-30
Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodyspl
-
2024-511209-49-00
6
2022-04-26
Patients with hormone receptor positive HER2 negative locally advanced
-
2023-505747-40-00
6
2022-04-20
Severe or Moderate Hemophilia A
-
2023-506361-56-00
5
2022-04-01
Endometrial cancer
-
2024-514497-41-00
10
2022-03-24
Trigeminal neuralgia
-
2023-504884-17-00
5
2022-02-04
Proteinuria
-
2023-506450-20-00
5
2021-11-05
Rheumatoid Arthritis
-
2023-506177-35-00
11
2021-10-23
Ovarian, fallopian tube, or primary peritoneal carcinoma.
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2024-510812-64-00
5
2021-09-30
Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin recep
-
2024-513091-17-00
5
2021-09-29
Progressive myopia
-
2024-512038-13-00
5
2021-09-16
Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
-
2023-510389-28-00
5
2021-06-14
short bowel syndrome
-
2024-517761-17-00
4
2021-05-31
Multiple Myeloma
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l